ABSTRACT Aim: Screening children with type 1 diabetes for coeliac disease is controversial, because they often appear asymptomatic. Our aim was to establish whether active screening should be recommended.
INTRODUCTION
Over the past few decades, we have witnessed a major increase in the clinical prevalence of coeliac disease (1) . One reason for this rapid change has been the recognition of specific at-risk groups, and the best know of these is type 1 diabetes (2). Due to the high concurrence of the two diseases, many guidelines recommend systematic screening for coeliac disease in patients with type 1 diabetes (3). Despite this, regular screening remains controversial because these children often appear to be asymptomatic (4) (5) (6) (7) (8) and most of the current guidelines focus on symptomatic patients (9, 10) . This, together with the fact that these subjects already have another chronic disease requiring continuous care, is considered to predispose them to poor adherence to the demanding and socially restrictive gluten-free diet. Some studies have shown dietary adherence to be as low as 25-30% in patients with coeliac disease and type 1 diabetes (11, 12) . It might also be argued that early diagnosis is not necessary, as screendetected children may have less severe intestinal damage (13) and thus a lower risk of complications from coeliac disease. These unsolved issues have led to substantial variations in the implementation of the current diagnostic guidelines in clinical practice (14) , especially when it comes to asymptomatic patients. So far, studies have focused mainly on the effects of the double diagnosis of coeliac disease and type 1 diabetes compared with just diabetes (4, (6) (7) (8) , and fewer studies have compared patients
Key Notes
This study aimed to establish whether the controversial practice of actively screening children with type 1 diabetes for coeliac disease should be recommended. It focused on 22 children whose coeliac disease was detected by serological screening during diabetes surveillance and 498 children diagnosed because of a clinical suspicion. Coeliac patients in both groups demonstrated signs of malabsorption and advanced mucosal damage, and our findings support active screening.
with coeliac disease and diabetes to those with just coeliac disease (15, 16) .
In Finland, the incidence of both coeliac disease and type 1 diabetes is among the highest in the world, and annual screening for coeliac disease has been routinely carried out in diabetic children since the turn of the 21st century. This provided us with an excellent opportunity to compare clinical and histological characteristics and dietary adherence between coeliac children diagnosed due to previous type 1 diabetes and those identified because of clinical suspicion.
METHODS

Patients and data collection
The study was conducted at the Center for Child Health Research at the University of Tampere and Tampere University Hospital, Finland. The cohort comprised 520 children aged 0-17 years with biopsy-proven coeliac disease, who were selected from our regularly updated research database. The patients in the database came from the catchment area of one tertiary centre, which covered approximately one million residents. Patient data were assembled from the medical reports, and inadequate data were complemented with personal interviews conducted by a study nurse with expertise in coeliac disease. The database included children detected in the clinic and following the screening of groups at risk of the disease. It also included children detected in prospective screening studies, but these children were excluded from the present study, as well as any children with an unclear coeliac disease diagnosis.
Clinical data, coeliac disease serology, other laboratory values and the severity of histological damage were collected from all patients at the time of the coeliac disease diagnosis. We also documented the adherence and clinical and serological response to a gluten-free diet. After the data collection, the study cohort was divided into two groups based on the diagnostic approach as follows: the type 1 diabetes group comprised children diagnosed with coeliac disease during regular diabetes surveillance and the clinical diagnosis group comprised children diagnosed due to a clinical suspicion of coeliac disease. We found that 42 of the study subjects had concomitant coeliac disease and type 1 diabetes. Of these, 22 were diagnosed with coeliac disease during annual serological surveillance for diabetes and comprised the type 1 diabetes group. The remaining 20 children with type 1 diabetes were first diagnosed with coeliac disease due to clinical suspicion and only developed diabetes later. Because the coeliac disease diagnosis was based on symptoms and reached before the diabetes diagnosis, these 20 patients were included in the control group (Fig. S1) .
The study protocol and the collection of the medical reports were approved by the Pediatric Clinic of Tampere University Hospital and the Ethics Committee of the Pirkanmaa Hospital District. All children and, or, their parents provided written informed consent in case personal interviews were required to supplement the data.
Data analyses
Clinical evaluation
The severity of symptoms at diagnosis was recorded before the gastroscopy for all patients, and they were then classified into four groups. Group 1 comprised screendetected asymptomatic patients, and group 2 were patients with mild symptoms, including occasionally disturbing gastrointestinal or extra-intestinal symptoms. Patients with moderate symptoms, namely a combination of symptoms or more distracting or frequent symptoms, were classified into group 3. Group 4 consisted of children with severe symptoms, meaning continuous symptoms that significantly disturbed their daily life, such as recurrent night-time awakenings due to pain or diarrhoea or symptoms requiring acute inpatient care. Poor growth was defined as a significant deceleration of growth compared with the nationally standardised reference rates for age and sex or lower than expected height than based on the mean parental heights (17) . If the parental heights were known, growth was considered abnormal if the current height of the child differed from the expected height by more than À2.3 standard deviation (SD). If the parental heights were not available, a maximum difference of À2.7 SD from the agebased and sex-based reference was allowed (18) . The possible presence of conditions associated with coeliac disease was also recorded, such as selective immunoglobulin A deficiency, autoimmune thyroidal disease, trisomy 21 and other chronic conditions, such as pollen allergy, inflammatory bowel disease, epilepsy and a family history of coeliac disease.
Coeliac disease serology and laboratory values
Serum endomysial antibodies were assessed at the Celiac Disease Research Center by an indirect immunofluorescence method using human umbilical cord as a substrate. A dilution of 1: ≥5 for endomysial antibodies was considered positive, and positive sera were further diluted to 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000 and 1:4000. Transglutaminase 2 antibodies have been measured routinely in our hospital from the early 2000s, but because of the diversity of assays and reference values, the results were not directly comparable. Serum haemoglobin (g/L) and mean corpuscular volume (fl) values at the time of the coeliac disease diagnosis were collected from all patients. Anaemia at diagnosis was defined as a haemoglobin value below the age-matched and sexmatched reference. Due to the known increased risk of autoimmune thyroidal disease in children with coeliac disease and type 1 diabetes, serum thyroid-stimulating hormone (TSH, mU/L) values were also collected when available.
Small-bowel mucosal morphology
Small-bowel mucosal morphology was assessed by hospital pathologists from a minimum of four biopsies taken from the distal duodenum during gastrointestinal endoscopy. From 2012 onwards, at least two to three biopsies were also routinely taken from the duodenal bulb. The coeliac disease diagnosis in this study was based on the demonstration of villous atrophy with crypt hyperplasia in well-oriented biopsy specimens. The degree of the mucosal lesion was further categorised as partial, subtotal and total villous atrophy. This well-established classification corresponds roughly to the Marsh-Oberhuber scores IIIa, IIIb and IIIc.
Dietary adherence and response to treatment All children with coeliac disease were referred to a dietician after the diagnosis for personal dietary guidance. A control visit to a dietitian was also recommended as part of our clinical routine, and most of the patients followed this recommendation. Adherence to the gluten-free diet was assessed after a median of 13 months by the dietitian or by a physician during a follow-up visit and grouped into three classes: children who adhered to a strict diet, children with occasional lapses, such as minor inadvertent gluten exposure less than once a month, and noncompliant children with one or more lapses a month. A good clinical response to the diet was defined as the disappearance of clinical symptoms, negative seroconversion or a marked decrease in coeliac autoantibodies and improvement of possible abnormal laboratory values and poor growth.
Statistics
Only unequivocal data were accepted for the analyses, and the laboratory values were excluded if there was a long delay between the blood sampling and diagnostic gastroscopy. The same applied if, for example, the degree of villous atrophy or dietary adherence was described imprecisely. Quantitative data are reported as medians with quartiles. Qualitative and categorical variables are expressed as percentages. The number of patients with data available on each specific variable is reported in the tables. Normally distributed variables were compared by the Student's t-test and skewed variables by the Mann-Whitney U-test. Cross-tabulation with chi-square was used to detect differences in categorical variables or, when the assumptions for chi-square were not met, by utilising Fisher's exact test. A p value of <0.05 was considered significant in all the analyses. Analyses were carried out using SPSS statistical software package version 22 (IBM Corp., Armonk, New York, USA).
RESULTS
The median age in 520 children in the study cohort was 7.8 years, and 63.8% were girls. The median age of the 22 children in the type 1 diabetes group was 7.3 years and 55% were girls, while the 498 children in the clinical suspicion group were a median of 7.9 years and 64% were girls. In clinically detected cases, 61.3% had gastrointestinal symptoms and 29.5% had extra-intestinal manifestations as the main presentation at diagnosis. Although all patients in the type 1 diabetes group were diagnosed as a result of diabetes surveillance, 55.0% of them reported unrecognised clinical symptoms or signs at the time of their coeliac disease diagnosis (Table 1) . However, these were less severe than in the clinically diagnosed patients (Fig. 1A) . There was no significant difference between the study groups in the severity of small-bowel mucosal atrophy at coeliac disease diagnosis (Fig. 1B) . Of note, half of those in the type 1 diabetes group already had subtotal or total villous atrophy. The children with type 1 diabetes who were detected by screening suffered less from poor growth at diagnosis than those in the clinical suspicion group (Table 2 ). There were also trends towards a lower prevalence of coeliac disease in the family and a higher prevalence of thyroidal disease and trisomy 21 in the type 1 diabetes group (Table 2) , whereas diagnoses of coeliac disease in toddlers were more common among the clinically detected children (Fig. 1C) . However, the differences were not significant. No other significant differences between the groups were demonstrated in any of the other clinical, serological and laboratory parameters (Tables 2 and 3) .
Patients in both groups showed equal adherence to the gluten-free diet (Fig. 1D ). In the type 1 diabetes group, one (6%) of the 16 children with precise dietary data had occasional dietary lapses and one (6%) frequent lapses. In the clinical suspicion group, 39 (14%) of the 278 children with data available had occasional lapses, with only one (0.4%) reporting frequent gluten consumption. The responses of the two groups to the dietary treatment were also comparable, as 94.7% of the screen-detected patients 
DISCUSSION
Our results demonstrate that children diagnosed with coeliac disease during type 1 diabetes surveillance did not differ in most of their clinical, serological and histological parameters from those found on a clinical basis. In addition, a substantial proportion of the children detected by screening had unrecognised clinical symptoms, and there was no difference between the two groups in terms of adherence or response to the diet. Therefore, our findings support the view that children with type 1 diabetes would benefit from regular serological screening for coeliac disease.
Despite the different diagnostic approach, almost half of the diabetic children detected with coeliac disease during screening reported symptoms at the time of their diagnosis, and the beneficial dietary response further substantiated the gluten dependency of these symptoms. This was in line with studies carried out in patients detected by other types of atrisk group screenings, for example first-degree relatives of coeliac disease patients (13, 19) . It also demonstrates that these individuals were very often not asymptomatic, just unrecognised. The prevalence of reported symptoms in patients with concomitant coeliac disease and type 1 diabetes has been reported to vary from zero to 85% depending on study design and definition of symptoms (4) (5) (6) 8, 12, 20) . It is true that in this study, and also in some previous studies, the coeliac symptoms in diabetic children have been mostly mild (5,21), but it should be realised that even these can cause a substantial burden and reduce the children's quality of life in the long term. In fact, as patients cannot compare their daily discomfort with that of others, they often accept it as an inevitable part of life and only recognise it afterwards as a consequence of untreated coeliac disease when they are on a gluten-free diet (13) . The wide spectrum and unspecific nature of the symptoms constitute a significant diagnostic challenge for physicians in daily practice and further support active screening for coeliac disease in patients with type 1 diabetes. Approximately half of the children in the type 1 diabetes group had already demonstrated subtotal or total villous atrophy at their coeliac disease diagnosis. This was in accordance with the few previous studies addressing this issue, which also found severe atrophy to be common among coeliac patients with concomitant diabetes (7, 8, 16) . Furthermore, we found no difference between the groups in serum endomysial antibody titres at the time of diagnosis.
Together, these findings demonstrate that, in spite of an often seemingly mild clinical presentation, even screendetected coeliac patients with diabetes may already have a well-advanced histological and serological disease. It is important to realise that ongoing mucosal damage may predispose unrecognised coeliac patients to excessive use of medication and healthcare services (22) and to serious long-term complications (23) . Accordingly, symptoms were also present in a substantial percentage of the children detected by screening, even if they were less common than among those detected in clinical practice. Furthermore, although anaemia was rarer in screened patients rather than in those detected due to clinical suspicions, some of the patients with diabetes and coeliac disease already had this deficiency and poor growth at the time of their coeliac disease diagnosis. Similar results have previously been reported by Tsouka et al. (15) , and it is evident that these patients are at risk of progressing towards an even more severe disease if not diagnosed and placed on dietary treatment. This issue is of particular importance in diabetic children, as it is known that concomitant type 1 diabetes further predisposes coeliac disease patients to a complicated disease course (24, 25) . In general, a delay in diagnosis could lead to various consequences of untreated coeliac disease, and screening has been proved to constitute a significant protective factor against the delay and subsequent unnecessary burden of the disease. (26) A necessary prerequisite for active screening for any disease is that the patient adapts to the treatment. Thus, one finding of particular importance here was the equal adherence to the gluten-free diet regardless of the diagnostic approach. The high self-reported compliance was further confirmed by the excellent clinical and serological response to the diet. Because of the different study designs, it was difficult to compare our study with previous works. For instance, adherence has been estimated using a range of serological or histological criteria, patients might have switched from a regular to a gluten-free diet in the course of the study (7, 27) , or noncompliant subjects might have been excluded. Notwithstanding these discrepancies, at least one previous study found that compliance in children with type 1 diabetes was comparable with our figures (27) . Moreover, our results were in line with those of a few recent studies conducted in patients screened for coeliac disease for reasons other than preceding diabetes (28, 29) . One factor promoting good adherence could be the parents' desire to optimise their child's health by treating the disease as well as possible, and the frequent follow-up of diabetes probably lends further support. In spite of the good results here, we recognise that daily motivation to adherence can be challenging, particularly in asymptomatic individuals with another burdensome disease (30) . In our opinion, however, the families should at least be aware of the presence of untreated coeliac disease and the potential associated complications, and consider whether the diet should be started.
The major limitations of the study were the retrospective design and the limited number of children with concomitant type 1 diabetes and coeliac disease. It is possible that significant differences, for example in the severity of villous atrophy, would have been found with a larger cohort of screening-detected type 1 diabetes patients. The small group size was, however, partly a consequence of the strict inclusion criteria, as we only accepted 22 children screened during routine surveillance for the type 1 diabetes group, while the other 20 whose diabetes was found after coeliac disease were placed in the control group. In the future, larger study cohorts obtained by a multicentre approach might provide further evidence of our results. An additional limitation is that there was missing data for several variables, caused mainly by our decision to accept only unequivocal results. One intrinsic problem of the retrospective study design is the possibility of recall bias in symptoms at the time of gastroscopy, when the families already knew about the possibility of coeliac disease. Evaluation of the symptoms could also have been improved using a validated questionnaire. Another limitation is that we did not investigate the effect of the gluten-free diet on the metabolic control of type 1 diabetes, but, based on previous evidence, a well-designed diet may even help to maintain a good glucose balance (8) . It must also be borne in mind that all Finnish children with coeliac disease receive monthly compensation and the disease is well known among physicians. Moreover, although maintaining strict dietary adherence is always challenging, it might be easier in Finland owing to the good availability of glutenfree products in the country. This is perhaps not the case in every country, but we demonstrated that at least in a supportive environment it is possible to achieve excellent dietary adherence in screening-detected coeliac patients with concomitant type 1 diabetes.
CONCLUSION
This study showed that the presentation of coeliac disease was largely comparable in children found by regular screening during type 1 diabetes follow-up visits and those diagnosed because of clinical suspicion. In particular, physicians should acknowledge that many diabetic children may suffer from unrecognised coeliac disease symptoms and have a well-advanced villous atrophy with a subsequent increased risk of long-term complications. The excellent adherence and response to the dietary treatment demonstrated in this study further advocates active screening for coeliac disease in children with type 1 diabetes.
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